331 related articles for article (PubMed ID: 25304791)
1. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
[TBL] [Abstract][Full Text] [Related]
2. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.
Ben Aicha I; Hathout L; Carignan D; Després P; Lavallée MC; Aubin S; Beaulieu L; Lacroix F; Foster W; Martin AG; Vigneault E
Brachytherapy; 2020; 19(5):584-588. PubMed ID: 32928485
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
4. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
5. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
[TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
7. Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
Peters M; Hoekstra CJ; van der Voort van Zyp JR; Westendorp H; van de Pol SM; Moerland MA; Maenhout M; Kattevilder R; van Vulpen M
Brachytherapy; 2016; 15(1):85-93. PubMed ID: 26614233
[TBL] [Abstract][Full Text] [Related]
8. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
9. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
10. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
11. Validation of the bladder neck as an important organ at risk in prostate seed brachytherapy based on D
Wallace ND; Olden KL; Brennan VS; Samuji MM; Jamaluddin MF; McVey G; Dunne MT; Kelly PJ
J Contemp Brachytherapy; 2023 Apr; 15(2):96-102. PubMed ID: 37215610
[TBL] [Abstract][Full Text] [Related]
12. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
13. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
14. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy.
Boyce-Fappiano D; Bathala TK; Ye R; Pasalic D; Gjyshi O; Pezzi TA; Noticewala SS; McGinnis GJ; Maroongroge S; Kuban DA; Nguyen QN; McGuire SE; Hoffman KE; Choi S; Tang C; Kudchadker RJ; Frank SJ
Brachytherapy; 2020; 19(5):574-583. PubMed ID: 32682778
[TBL] [Abstract][Full Text] [Related]
15. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
17. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
18. Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.
Smith RP; Jones HA; Beriwal S; Gokhale A; Benoit R
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):745-50. PubMed ID: 20888139
[TBL] [Abstract][Full Text] [Related]
19. Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy.
Roshan D; Joyce K; Woulfe P; Gorakati PR; Stock R; Sullivan FJ
Brachytherapy; 2021; 20(4):873-882. PubMed ID: 33840634
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
